CN110325527B - 作为细胞外柠檬酸盐摄取的抑制剂的磺酰胺 - Google Patents
作为细胞外柠檬酸盐摄取的抑制剂的磺酰胺 Download PDFInfo
- Publication number
- CN110325527B CN110325527B CN201780074706.4A CN201780074706A CN110325527B CN 110325527 B CN110325527 B CN 110325527B CN 201780074706 A CN201780074706 A CN 201780074706A CN 110325527 B CN110325527 B CN 110325527B
- Authority
- CN
- China
- Prior art keywords
- group
- substituted
- salt
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16203086 | 2016-12-09 | ||
| EP16203086.0 | 2016-12-09 | ||
| PCT/EP2017/081359 WO2018104220A1 (en) | 2016-12-09 | 2017-12-04 | Sulfonamides as inhibitors of the uptake of extracellular citrate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110325527A CN110325527A (zh) | 2019-10-11 |
| CN110325527B true CN110325527B (zh) | 2022-08-09 |
Family
ID=57539116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780074706.4A Active CN110325527B (zh) | 2016-12-09 | 2017-12-04 | 作为细胞外柠檬酸盐摄取的抑制剂的磺酰胺 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10793522B2 (enExample) |
| EP (1) | EP3551618B1 (enExample) |
| JP (1) | JP7007381B2 (enExample) |
| CN (1) | CN110325527B (enExample) |
| WO (1) | WO2018104220A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7007381B2 (ja) | 2016-12-09 | 2022-01-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 細胞外クエン酸の取込みの阻害剤としてのスルホンアミド |
| GB2560713A (en) * | 2017-03-20 | 2018-09-26 | Eternygen Gmbh | Inhibitor of citrate transporter |
| GB201918410D0 (en) * | 2019-12-13 | 2020-01-29 | Z Factor Ltd | Compounds and their use for the treatment of alpha1-antitrypsin deficiency |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010080183A1 (en) * | 2009-01-08 | 2010-07-15 | The Trustees Of Columbia University In The City Of New York | Potent non-urea inhibitors of soluble epoxide hydrolase |
| WO2015008872A1 (en) * | 2013-07-17 | 2015-01-22 | Otsuka Pharmaceutical Co., Ltd. | Cyanotriazole compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5219150B2 (ja) | 2005-12-12 | 2013-06-26 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害薬として活性な置換ピラゾロ［４，３−ｃ］ピリジン誘導体 |
| US20100286145A1 (en) | 2007-07-26 | 2010-11-11 | Comentis, Inc. | Isophthalamide derivatives inhibiting beta-secretase activity |
| US8258158B2 (en) | 2009-09-11 | 2012-09-04 | Hoffmann-La Roche Inc. | HSL inhibitors useful in the treatment of diabetes |
| CA2844730A1 (en) | 2011-09-01 | 2013-03-07 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
| JP7007381B2 (ja) | 2016-12-09 | 2022-01-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 細胞外クエン酸の取込みの阻害剤としてのスルホンアミド |
-
2017
- 2017-12-04 JP JP2019530714A patent/JP7007381B2/ja active Active
- 2017-12-04 EP EP17811906.1A patent/EP3551618B1/en active Active
- 2017-12-04 US US16/467,499 patent/US10793522B2/en active Active
- 2017-12-04 CN CN201780074706.4A patent/CN110325527B/zh active Active
- 2017-12-04 WO PCT/EP2017/081359 patent/WO2018104220A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010080183A1 (en) * | 2009-01-08 | 2010-07-15 | The Trustees Of Columbia University In The City Of New York | Potent non-urea inhibitors of soluble epoxide hydrolase |
| WO2015008872A1 (en) * | 2013-07-17 | 2015-01-22 | Otsuka Pharmaceutical Co., Ltd. | Cyanotriazole compounds |
Non-Patent Citations (1)
| Title |
|---|
| Optimization of a Dicarboxylic Series for in Vivo Inhibition of Citrate Transport by the Solute Carrier 13 (SLC13) Family;Kim Huard et al.;《Optimization of a Dicarboxylic Series for in Vivo Inhibition of Citrate Transport by the Solute Carrier 13 (SLC13) Family》;20160106;第59卷;1165-1175 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200062708A1 (en) | 2020-02-27 |
| WO2018104220A1 (en) | 2018-06-14 |
| CN110325527A (zh) | 2019-10-11 |
| JP2020500907A (ja) | 2020-01-16 |
| US10793522B2 (en) | 2020-10-06 |
| JP7007381B2 (ja) | 2022-01-24 |
| EP3551618B1 (en) | 2020-09-16 |
| EP3551618A1 (en) | 2019-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4563199A2 (en) | Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | |
| EP2831059B1 (en) | Processes for preparing tubulysin derivatives and conjugates thereof | |
| BR112020011779A2 (pt) | derivados de sulfonil ureia como moduladores de inflamassona nlrp3 | |
| KR102336370B1 (ko) | 당뇨병과 같은 질환의 치료를 위한 피롤리딘 gpr40 조정제 | |
| JPH07196658A (ja) | 縮合多環式ラクタム含有化合物 | |
| JP2001519812A (ja) | ソマトスタチン作動薬 | |
| JP2001518895A (ja) | ソマトスタチン作働薬 | |
| JP2008545780A (ja) | 有機化合物 | |
| US9000182B2 (en) | 2H-imidazol-4-amine compounds and their use as BACE inhibitors | |
| US9000185B2 (en) | Cycloalkyl ether compounds and their use as BACE inhibitors | |
| CN110325527B (zh) | 作为细胞外柠檬酸盐摄取的抑制剂的磺酰胺 | |
| US9000184B2 (en) | Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors | |
| TWI821169B (zh) | 免疫蛋白酶體抑制劑 | |
| AU2008320718B2 (en) | Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof | |
| CA2824536A1 (en) | Protease activated receptor 2 (par2) antagonists | |
| WO2002000606A1 (en) | Biphenyl compound | |
| EP3873599A1 (en) | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof | |
| US9340573B2 (en) | Azaindolines | |
| CN114641466B (zh) | 磺酰脲衍生物及其用途 | |
| KR102502046B1 (ko) | Cxcr7 수용체 작동제 (3s,4s)-1-시클로프로필메틸-4-｛[5-(2,4-디플루오로-페닐)-이속사졸-3-카르보닐]-아미노｝-피페리딘-3-카르복실산 (1-피리미딘-2-일-시클로프로필)-아미드의 결정질 형태 | |
| WO2024026262A1 (en) | Substituted pyrazolyl-pyridinyl compounds as ligand directed degraders of irak3 | |
| WO2004002956A2 (en) | Asymmetric synthesis of amino-pyrrolidinones and a crystalline, free-base amino-pyrrolidinone | |
| JPH05271187A (ja) | ピロリジン誘導体又はその薬学的に許容される塩 | |
| HK1192230A (en) | Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof | |
| CZ2001742A3 (cs) | Nové deriváty přírodních látek |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |